TY - JOUR
T1 - Ultralow Limit Detection of Soluble HER2 Biomarker in Serum with a Fiber-Optic Ball-Tip Resonator Assisted by a Tilted FBG
AU - Sypabekova, Marzhan
AU - Amantayeva, Aida
AU - Vangelista, Luca
AU - González-Vila, Álvaro
AU - Caucheteur, Christophe
AU - Tosi, Daniele
N1 - Funding Information:
This work was funded by grants SMARTER (091019CRP2117) and EPICGuide (240919FD3908) at Nazarbayev University and by the NATO Science for Peace and Security program (grant G5486).
Publisher Copyright:
© 2022 The Authors. Published by American Chemical Society.
PY - 2022/8/17
Y1 - 2022/8/17
N2 - An optical-fiber biosensor has been developed for the detection of the breast cancer biomarker soluble human epidermal growth factor receptor-2 (sHER2). The sensor was fabricated by combining a tilted fiber Bragg grating (TFBG) with a ball resonator, allowing us to achieve an excellent sensitivity compared to other optical-fiber-based sensors. The sensor exhibits a resonance comb excited by the TFBG and the spectral profile of the ball resonator. The detection of sHER2 at extremely low concentrations was carried out by tracking the amplitude change of selected resonances. The therapeutic anti-HER2 monoclonal antibody Trastuzumab has been used to functionalize the biosensor with silane surface chemistry. The sensor features a sensitivity of 4034 dB/RIU with a limit of detection (LoD) in buffer and in a 1/10 diluted serum of 151.5 ag/mL and 3.7 pg/mL, respectively. At relatively high protein concentrations (64 ng/mL) binding to sHER (7.36 dB) as compared to control proteins (below 0.7 dB) attested the high specificity of sHER2 detection.
AB - An optical-fiber biosensor has been developed for the detection of the breast cancer biomarker soluble human epidermal growth factor receptor-2 (sHER2). The sensor was fabricated by combining a tilted fiber Bragg grating (TFBG) with a ball resonator, allowing us to achieve an excellent sensitivity compared to other optical-fiber-based sensors. The sensor exhibits a resonance comb excited by the TFBG and the spectral profile of the ball resonator. The detection of sHER2 at extremely low concentrations was carried out by tracking the amplitude change of selected resonances. The therapeutic anti-HER2 monoclonal antibody Trastuzumab has been used to functionalize the biosensor with silane surface chemistry. The sensor features a sensitivity of 4034 dB/RIU with a limit of detection (LoD) in buffer and in a 1/10 diluted serum of 151.5 ag/mL and 3.7 pg/mL, respectively. At relatively high protein concentrations (64 ng/mL) binding to sHER (7.36 dB) as compared to control proteins (below 0.7 dB) attested the high specificity of sHER2 detection.
KW - cancer biomarker detection
KW - cancer diagnostic
KW - fiber Bragg grating
KW - HER2 detection
KW - human epidermal growth factor-2 (HER2)
KW - low-limit biosensor
KW - optical-fiber biosensors
UR - http://www.scopus.com/inward/record.url?scp=85128695181&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128695181&partnerID=8YFLogxK
U2 - 10.1021/acsmeasuresciau.2c00008
DO - 10.1021/acsmeasuresciau.2c00008
M3 - Article
AN - SCOPUS:85128695181
SN - 2694-250X
VL - 2
SP - 309
EP - 316
JO - ACS Measurement Science Au
JF - ACS Measurement Science Au
IS - 4
ER -
